Selin Merih Urlu

Dr. Selin Merih Urlu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Hematology
Verified
Journal Article
Open access
SUSelin Merih Urlu
Selin Merih Urlu
MÖMuhit Özcan
Muhit Özcan
Acute Myeloid Leukemia (AML) has been the subject of extensive study by medical professionals and researchers. It is a well-documented type of leukemia, and our understanding of AML has advanced through the efforts of many individuals in the fields of hematology and oncology. There is currently an ongoing and gradual revolution in the research and treatment of acute myeloid leukemia. Recent years have seen significant progress due to advancements in technology, which have played a critical role in untangling the complexities of AML. The history of AML treatment has witnessed remarkable advancements, transitioning from limited options in the early twentieth century to a more refined and targeted approach in the twenty-first century. Continuous research and innovation offer hope for further progress in the field.

25 August 2022 in LLM Dergi
Verified
Journal Article
Closed access
UŞUğur Şahin
Uğur Şahin
AAAykut İlker Arslan
Aykut İlker Arslan
SUSelin Merih Urlu
Selin Merih Urlu
AGAyla Gökmen
Ayla Gökmen
ESEnder Soydan
Ender Soydan

26 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EIEmel Isleyen
Emel Isleyen
NANurcan Alhan
Nurcan Alhan
EDEsra Terzi Demirsoy
Esra Terzi Demirsoy
AGAyfer Gedük
Ayfer Gedük
DADuygu Nurdan Avci
Duygu Nurdan Avci
OMOzgur Mehtap
Ozgur Mehtap
Background: Classical Hodgkin lymphoma (cHL) demonstrates high survival rates with the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine); however, the use of bleomycin is associated with a significant risk of pulmonary toxicity. The Risk-Adapted Treatment of HL (RATHL) trial demonstrated that omitting bleomycin in patients with favorable interim Positron Emission Tomography (PET-CT) results did not adversely affect survival outcomes. In this study, we present real-world data from advanced-stage HL patients treated according to the RATHL protocol. Methods: This multicenter, retrospective study included newly diagnosed cHL patients with Ann Arbor stage IIB–IV disease or stage IIA disease with bulky disease or with involvement of three or more sites, enrolled from 29 centers across Türkiye. The analysis focused on patients whose initial treatment was de-escalated from ABVD to AVD (bleomycin was omitted). Data were collected on demographic and clinical prognostic characteristics, interim PET-CT findings (evaluated using the Deauville score), progression-free survival (PFS) and overall survival (OS). Survival outcomes were assessed using Kaplan–Meier analysis. Results: A total of 379 patients were included, with a median age of 34 years (range: 18–78). Following interim PET-CT assessments (After 2 cycles of ABVD), Deauville scores were 1 in 39.8% of patients, 2 in 39.1%, and 3 in 21.1%. Based on these results, bleomycin was omitted immediately after interim PET-CT in 73.9% of patients, after one additional ABVD cycle in 12.1%, and after two additional cycles in 14%. The median follow-up duration was 28 months (range: 6–96). The 3-year PFS and OS rates were 86.0% and 96.1%, respectively. Patients with Deauville scores of 1–2 had a 3-year PFS rate of 87.6%, compared to 79.8% in those with a score of 3 (p = 0.087). Increased age, poor Eastern Cooperative Oncology Group Scale (ECOG) performance status, bulky disease, and higher International Prognostic Scores (IPS) were significantly associated with inferior OS (p < 0.05). There were no significant differences in OS among patients who received 2, 3, or 4 cycles of ABVD. However, among patients treated with 2 cycles of ABVD, both extranodal involvement (p = 0.039) and higher IPS (p = 0.002) were significantly associated with decreased PFS. Conclusions: Our findings demonstrate that PET-guided de-escalation of bleomycin after two cycles of ABVD is feasible, effective, and safe in real-world multicenter practice in Türkiye. The survival outcomes are comparable to those reported in the RATHL study, reinforcing the role of interim PET-CT in guiding individualized therapy. However, patients with high IPS or extranodal involvement may require more tailored management strategies.

6 December 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
USUgur Sahin
Ugur Sahin
SUSelin Merih Urlu
Selin Merih Urlu
AGAyla Gokmen
Ayla Gokmen
OAOnder Arslan
Onder Arslan
MOMuhit Ozcan
Muhit Ozcan

3 December 2024 in LLM Dergi
Verified
Journal Article
Closed access
SUSelin Merih Urlu
Selin Merih Urlu
UŞUğur Şahi̇n
Uğur Şahi̇n
AGAyla Gökmen
Ayla Gökmen
ÖAÖnder Arslan
Önder Arslan
MÖMuhit Özcan
Muhit Özcan

30 March 2022 in LLM Dergi
Verified
Journal Article
Closed access
UŞUğur Şahin
Uğur Şahin
ESEnder Soydan
Ender Soydan
SUSelin Merih Urlu
Selin Merih Urlu
MOMevlüde Kurdal Okcu
Mevlüde Kurdal Okcu
OÖOzan Özkumur
Ozan Özkumur
AGAyla Gökmen
Ayla Gökmen